[ORGANIZATION]
Oruka Therapeutics
Featured in 2 tracked stories · first seen
Situations
Oruka Therapeutics drug development expansion
2 clusters · 5 sources · last updated
Latest: Oracle and Sumitomo Mitsui see notable stock transactions
Oruka Therapeutics has expanded the development rights for its lead IL-23 program, ORKA-001, to include inflammatory bowel disease (IBD) following an amended license agreement with Paragon Therapeutics. The company is cu